title: Sorafenib in metastatic MTC - a case report and minireview of the literature.
abstract: Medullary thyroid cancer (MTC) is a rare and only surgically treatable disease with early development of metastases and bad prognosis. Due to the lack of efficient systemic treatment, new strategies and approaches are needed to better the patients' outcome. One of the most promising treatment options is the use of tyrosine multikinase inhibitors, which appear to have some effect on the disease progression with tolerable toxicity. Most of them affect many key pathways in the cancer genesis and have proven their effect in different malignancies. We report a case of a young patient with metastatic MTC treated successfully for two months with sorafenib.
authors.affiliation: Hematology and Oncology Department, Medical Military Academy, Sofia, Bulgaria.
authors.forename: Mila
authors.initials: M
authors.lastname: Petrova
authors.forename: Zhasmina
authors.initials: Z
authors.lastname: Mihaylova
authors.forename: Albena
authors.initials: A
authors.lastname: Fakirova
keywords: TKIs; cardiotoxicity; medullary thyroid cancer; tumor response